ENO1,  the core catalytic enzyme of glycolysis, has been implicated in tumor initiation and progression of numerous cancers through canonical metabolic pathways or non‐metabolic atypical pathways, including CRC and LIHC.[47, 48, 49, 50, 51, 52] Typically, m5C‐modified RNA is recognized by reader proteins, allowing it to exert its functions such as enhancing RNA stability in an m5C‐dependent manner.[10, 18] Subsequent mass spectrometry analysis was conducted, identifying YBX1 as a mediator of m5C‐ENO1. The gene discussed is ENO1; the disease is neoplasm.